The innovative biopharmaceutical company PROMOMED announces the successful IPO and closing of the application book at the upper limit of the range

July 12, 2024, Moscow. The leading innovative biopharmaceutical company PJSC PROMOMED (formerly –PROMOMED", the "Company", the "Issuer" and, together with its subsidiaries, the "Group") announces the successful holding of an initial public offering (hereinafter referred to as the "IPO" or the "Offer") and the commencement of trading in ordinary shares (hereinafter referred to as the "Shares") on the Moscow Stock Exchange under the ticker PRMD from July 12, 2024.

Key results

-The placement attracted interest from various investor groups. The demand from retail and institutional investors has significantly exceeded the supply volume.
-The price of one Share was 400 rubles, which corresponds to the upper limit of the price range. The volume of the placement amounted to ~ 6 billion rubles. A portion of this amount will be reserved for stabilization purposes.
-The stabilization of the Stock price at exchange auctions in the amount of up to 15% of the volume of Shares sold under the Offer will be valid for 30 days after the start of trading on the Moscow Stock Exchange. The shares were provided by the largest shareholder of the Company for the purpose of stabilization.
-Following the results of the IPO, the Company's market capitalization will amount to 85 billion rubles.
-The company will use the funds raised following the IPO primarily for the development, registration and market launch of new innovative drugs. The Company will consider options for partially reducing its debt burden and optimizing its capital structure.
-According to the results of the IPO, the largest shareholder of the Issuer will retain a controlling stake in the authorized capital of the Company.
-Trading in Shares will begin on July 12, 2024 under the ticker PRMD and ISIN RU000A108JF7.
-The Company's shares will be on the second quotation list of securities admitted to trading on the Moscow Stock Exchange.
-The current shareholder has assumed obligations limiting the disposal of Shares within 180 days after the completion of the IPO

Alexander Yefremov, CEO of PJSC PROMOMED, commented:

"Today we are announcing a successful IPO PROMOMED. A well-thought–out strategy based on innovation in development and technological advantages in production, and a sustainable business model of development attracted the largest funds and private investors who saw the potential for multiple growth of the Company and invested in innovations in biopharmaceuticals, a new, rapidly growing branch of medicine. We will use the funds raised to bring to the market as soon as possible a wide portfolio of the latest drugs in Endocrinology, Oncology, Neurology, Immunology and other therapeutic areas. These drugs will become the main assistants of doctors and patients, and will change our current understanding of the treatment of the most serious diseases."

Allocation results

● The Company adhered to the principles outlined earlier, trying to ensure a balanced allocation between retail and institutional investors, as well as key top managers, employees and partners of the Company:

-Allocation to institutional investors amounted to 82.5% of the Supply volume;

-Allocation to retail investors amounted to 13.9% of the Supply volume:

-Allocation to key top managers, employees and partners of the Company amounted to 3.6% of the size of the Offer.

Contacts

For investors
ir@promomed.pro

For the media
pr@promomed.pro

This message and the information contained therein are not:

● an offer to purchase any securities,
● an invitation to make offers to purchase any securities,
● part of such offers or invitations,
● advertising of securities in the Russian Federation or other jurisdictions,
● encouraging or recommending transactions,
● and also cannot be interpreted as such.

Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.

Neither this announcement nor any part of it should serve as a basis for making any investment decisions.

The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). Information providedThe information contained in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED (hereinafter referred to as the Company) is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the sole source of information when making an investment decision.

Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the prospectus of securities – ordinary shares of the Company and other information disclosed on the Company's website. https://e-disclosure.ru/portal/company.aspx?id=38533 .

The information contained in this announcement may include estimates and other forward–looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Company and a group of persons controlled by the Company (hereinafter referred to as the Group). Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions provided in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). The indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.

The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.

The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.